| |
| |
| TALENT PERFORMANCE |
| EMPLOYEE STRENGTH |
| Total Employees |
| Year |
|
Including Aurigene |
|
Excluding Aurigene |
| FY13-14 |
|
18,647 |
|
18,118 |
| FY14-15 |
|
20,372 |
|
19,855 |
|
| |
| Attrition Rate |
 |
| |
|
 |
|
| Region-wise Workforce |
| Including Aurigene |
|
|
|
| Germany# | 165 |
Russia CIS ## | 1,628 |
|
| |
|
|
| North America | 671 |
India | 15,509 |
|
|
|
|
| UK** | 415 |
Rest of the World*** | 259 |
|
| |
|
|
| FY13-14 |
|
|
| Total: 18,647 |
|
|
| |
|
|
| |
|
|
| Germany# | 158 |
Russia CIS ## | 1,720 |
|
| |
|
|
| North America | 689 |
India | 17,043 |
|
|
|
|
| UK** | 367 |
Rest of the World*** | 395 |
|
| |
|
|
| FY14-15 |
|
|
| Total: 20,372 |
|
|
| |
|
|
|
|
** Includes Chirotech Facility-India and US
*** Includes - Mexico, Brazil, Venezuela, South Africa,
China ANZ, Jamaica, Sri Lanka, Myanmar, Vietnam,
UAE, Spain, Romania, Italy
## includes GG EM
# includes- betapharm, GG Europe |
| |
|
|
| |
| Gender Breakup |
| Total Employees |
|
FY14-15 |
| Male |
|
16,782 |
| Female |
|
3,073 |
|
|
|
* Break up of India-based employees
(excludes Aurigene) |
|
| |
|
| Employment Type by Geography |
| Permanent Employees |
| As of March 31, 2015 |
Rest of the World* |
|
US |
|
Europe# |
|
Total |
| Manufacturing (1) |
9,850 |
|
138 |
|
422 |
|
10,410 |
| Sales & Marketing (2) |
6,351 |
|
40 |
|
139 |
|
6,530 |
| R&D |
995 |
|
175 |
|
8 |
|
1,178 |
| Others (3) |
2,056 |
|
58 |
|
140 |
|
2,254 |
| Total |
19,252 |
|
411 |
|
709 |
|
20,372 |
|
|
#Europe: UK, Germany, Chirotech, Spain, Romania & Italy.
*ROW: India, Mexico, Aurigene, Russia, CIS, Brazil, Venezuela, South Africa, China, ANZ, Jamaica, Sri Lanka, Myanmar, Vietnam, UAE. |
| |
(1) Includes quality, technical services and warehouse.
(2) Includes business development.
(3) Includes shared services, corporate business development and the intellectual property management team. |
| |
| Cadre-wise Breakup |
| Employee Group |
Female |
|
Male |
|
Total |
| Staff
|
358 |
|
1,535 |
|
1,893 |
| Trainee
|
295 |
|
1,789 |
|
2,084 |
| Junior Management |
2,335 |
|
12,760 |
|
15,095 |
| Middle Management |
161 |
|
946 |
|
1,107 |
| Senior Management |
16 |
|
177 |
|
193 |
| Grand Total |
|
|
|
|
20,372 |
|
| |
| *Includes Aurigene |
|
|
| Age-wise Breakup |
| Senior Management |
| |
|
FY14-15 |
| Under 30 |
|
0% |
| 30-50 |
|
58% |
| Over 50 |
|
42% |
|
|
|
| |
| BU-wise Turnover |
| FY14-15 |
| BU |
Voluntary Exits |
|
Total Exits |
|
Total Attrition |
|
Involuntary Attrition |
| Global Generics |
1,649 |
|
2,312 |
|
20.15% |
|
5.78% |
| Formulations Plants |
465 |
|
741 |
|
16.72% |
|
6.23% |
| India - Field |
878 |
|
1,087 |
|
24.75% |
|
4.76% |
| India - Head Office |
16 |
|
21 |
|
9.21% |
|
2.19% |
| Emerging Markets |
212 |
|
363 |
|
21.54% |
|
8.96% |
| North America Generics |
57 |
|
71 |
|
12.23% |
|
2.41% |
Global Generics
- EU
(Includes Betapharm) |
21 |
|
29 |
|
8.47% |
|
5.10% |
| PSAI |
568 |
|
1,008 |
|
19.00% |
|
8.29% |
| API plants |
462 |
|
893 |
|
19.86% |
|
9.58% |
| CTO- Cuernavaca |
15 |
|
18 |
|
6.84% |
|
1.14% |
| CPS (Includes Chirotech) |
61 |
|
64 |
|
18.74% |
|
0.88% |
| API Office |
30 |
|
33 |
|
16.18% |
|
1.47% |
| Corporate |
74 |
|
78 |
|
26.71% |
|
1.37% |
| Biologics |
78 |
|
87 |
|
16.13% |
|
1.67% |
| IPDO- India |
151 |
|
180 |
|
17.09% |
|
2.75% |
| IPDO- Chirotech |
6 |
|
6 |
|
13.33% |
|
0.00% |
| Octoplus |
14 |
|
21 |
|
16.41% |
|
5.47% |
| Proprietary Products- India |
16 |
|
17 |
|
10.97% |
|
0.65% |
| Proprietary Products-US |
6 |
|
7 |
|
7.53% |
|
1.08% |
| Total |
2,557 |
|
3,716 |
|
19.47% |
|
6.07% |
|
|
| |
| |
|
